The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.
Esperantra, a non-profit organization working to reduce cancer mortality in Peru, has generously agreed to partner with The Max Foundation to facilitate the importation of medicines within Max Access Solutions.
“Esperantra and The Max Foundation are a perfect fit together,” said Inés García González, The Max Foundation’s Region Head for Latin America. “Our organizations have similar goals – expanding access to treatment, reducing cancer mortality, etc. – and Esperantra is a well-established organization in Peru with a great track record. We are honored to partner with them.”
Karla Ruiz de Castilla, Esperantra’s Executive Director, said: “It is our pleasure to partner with The Max Foundation and help expand access to treatment for patients in Peru. Together we are improving clinical outcomes and quality of life for people facing cancer.”
Thanks to the partnership with Esperantra, Peru has become the 70th country to have patients enrolled in Max Access Solutions.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Pat Garcia-Gonzalez, CEO of The Max Foundation presented data from our access to CML treatment program, including a treatment free remission support program we have implemented across low-and middle-income countries. After her presentation, she was interviewed by The Video Journal of Hematology and Hematological….
The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support. “Dr. Wagner has gone above and beyond in advising our….
We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs. Bryan joins the team with more than 18 years of experience building and leading high-impact mission-driven teams, most recently as Commercialization Lead for Medical Technologies at Global Good at Intellectual Ventures. Previously he….
